EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Relationships of B12 and Homocysteine with Outcomes in the SURE-PD, SURE-PD3, and STEADY-PDIII Trials

Chadwick W Christine, Peggy Auinger, Esther A R Forti, Lyvin Tat, Noemi Cannizzaro, Arshi Mustafa, Jay M Iyer, David Oakes, Ralph Green

Journal of Parkinson’s Disease · 2024

DOI: 10.3233/jpd-240035 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Parkinson’s Disease, 2024. Verfasst von Chadwick W Christine und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of California San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Vitamin B 12, Homocysteine, Parkinson Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

DATATOP was a study of early Parkinson’s disease (PD) conducted in the 1980 s, before mandatory folic acid fortification in the United States. Our analysis of its baseline serum samples revealed a geometric mean vitamin B12 of 369 pg/mL and homocysteine (tHcy) of 9.5μmol/l. We also found that low B12 predicted greater worsening of ambulatory capacity (AC) and elevated tHcy (>15μmol/L) predicted greater declines in cognitive function.

Objective

We sought to measure B12 and tHcy in contemporary trial participants with early PD who had not started dopaminergic treatment and to determine whether these analytes were associated with clinical progression.

Methods

We measured B12 and tHcy from baseline and end-of-study blood samples from three recent clinical trials.

Results

Baseline geometric mean B12 levels for these studies ranged from 484– 618 pg/ml and for tHcy ranged from 7.4– 10μmol/L. Use of B12-containing supplements ranged from 41– 61%, and those taking supplements had higher B12 and lower tHcy. Those who began levodopa, but were not taking B12-supplements, had greater end-of-study tHcy. There was no association of baseline tHcy > 15μmol/L with annualized change in Montreal Cognitive Assessment and no association of baseline B12 tertiles with change in AC.

Conclusions

In these longitudinal trials, B12 levels were higher than for DATATOP, due in large part to increased B12-supplement intake, while tHcy levels were similar. Initiation of levodopa was associated with increases of tHcy in those not taking a B12-containing supplement. These smaller studies did not replicate prior findings of low B12 and elevated tHcy with features of progression, possibly due to higher baseline B12.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vitamin B 12HomocysteineParkinson DiseaseHumansMaleFemaleAgedMiddle AgedDisease ProgressionAntiparkinson AgentsLevodopaDietary SupplementsCognitive Dysfunction

Stichwörter der Autor:innen

Nutritioncognitive impairmentgait instabilityleucine-rich repeat kinase 2neuroprotection

Substanzen

Vitamin B 12HomocysteineAntiparkinson AgentsLevodopa

Autor:innen und Institutionen

  • Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • Department of Neurology, Center for Health and Technology, University of Rochester, Rochester, NY, USA.
  • Department of Pathology and Laboratory Medicine, University of California Davis, Davis, CA, USA.
  • Departments of Molecular and Cellular Biology and Statistics, Harvard University, Cambridge, MA, USA.
  • Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY, USA.

Zitieren

APA

Christine, C. W., Auinger, P., Forti, E. A. R., Tat, L., Cannizzaro, N., Mustafa, A., Iyer, J. M., Oakes, D., & Green, R. (2024). Relationships of B12 and Homocysteine with Outcomes in the SURE-PD, SURE-PD3, and STEADY-PDIII Trials. Journal of Parkinson’s Disease. https://doi.org/10.3233/jpd-240035

Vancouver

Christine CW, Auinger P, Forti EAR, Tat L, Cannizzaro N, Mustafa A, et al. Relationships of B12 and Homocysteine with Outcomes in the SURE-PD, SURE-PD3, and STEADY-PDIII Trials. Journal of Parkinson’s Disease. 2024. doi:10.3233/jpd-240035

BibTeX
@article{Christine2024,
  author = {Christine, Chadwick W and Auinger, Peggy and Forti, Esther A R and Tat, Lyvin and Cannizzaro, Noemi and Mustafa, Arshi and Iyer, Jay M and Oakes, David and Green, Ralph},
  title = {Relationships of B12 and Homocysteine with Outcomes in the SURE-PD, SURE-PD3, and STEADY-PDIII Trials},
  journal = {Journal of Parkinson’s Disease},
  year = {2024},
  doi = {10.3233/jpd-240035}
}
Kostenlos starten →